I. Laszlovszky

P.3.d.025 Safety and tolerability of cariprazine in long-term treatment of schizophrenia: integrated summary of safety data

Schizophrenia is a chronic disorder that is associated with morbidity, mortality, and functional impairment. Long‐term antipsychotic treatment is usually required, but many patients discontinue therapy due to tolerability issues associated with the medication. Cariprazine, a potent dopamine D3 and D2 receptor partial agonist with preferential binding to D3 receptors, is in clinical development for the treatment of schizophrenia, bipolar mania, bipolar depression, and the adjunctive treatment of major depressive disorder (MDD). The efficacy and safety of cariprazine in patients with acute exacerbation of schizophrenia was established in 3 Phase II/III clinical trials.1‐3 Pooled data from 2 open‐label studies (NCT011047924 and NCT008398525) evaluated the long‐term safety and tolerability of cariprazine in patients with schizophrenia.